ClinicalTrials.Veeva

Menu

Personalized Stimulation Loop for Neurorehabilitation in Parkinson: a Proof-of-principle Study (StimuLOOP_PD-S)

University of Zurich (UZH) logo

University of Zurich (UZH)

Status

Enrolling

Conditions

Parkinson Disease

Treatments

Other: TASS Intervention (Verum)
Other: TASS Intervention (Sham)

Study type

Interventional

Funder types

Other

Identifiers

NCT07082595
2024-01941 (Other Identifier)
StimuLOOP_PD-S

Details and patient eligibility

About

Parkinson's disease (PD) is a neurodegenerative disease that affects about 1% of the elderly population and accounts for substantial disability and health care costs. Disability is largely driven by mobility deficits caused by impaired gait. Effective treatments are available to restore lower limb function and improve gait, but response to treatment varies greatly from patient to patient and often shows only small effect sizes. Addressing this heterogeneity requires personalization, a concept referred to precision neurorehabilitation.

StimuLOOP.PD-Sleep intends to foster structured and reproducible methods for precision neurorehabilitation of gait in PD. The investigators will conduct a proof-of-concept study to investigate a sleep intervention tailored to the individual patient in the context of motor rehabilitation.

• Targeted auditory stimulation during sleep (TASS): The investigators aim to reactive rehabilitation-related memories through presentation of auditory stimuli during sleep with the goal of promoting motor memory consolidation into stable motor commands.

The investigators will leverage TASS to enhance consolidation of the movement patterns that are learned during rehabilitation.

The investigators expect that this intervention will lead to greater gains in functional walking ability and balance. Beyond demonstrating a proof-of-concept for novel methods of applying TASS stimulation in the context of neurorehabilitation, positive results of this project may have implications for neurorehabilitation treatment in general by providing first insights into the benefits and interplay of TASS with a rehabilitation.

Enrollment

40 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Idiopathic Parkinson's disease with gait and postural stability deficits
  • ≥18 years of age
  • UPDRS III gait scores 1-3
  • UPDRS III postural instability scores 1-3
  • Prescribed rehabilitation therapy
  • Informed consent as documented by signature
  • Adjustments in dopaminergic medication and DBS stimulation to improve

Exclusion criteria

  • Cognitive impairment, Montreal Cognitive Assessment (MoCa) < 20
  • Other neurological or medical condition that caused sustained clinically relevant gait and/or postural stability deficits
  • History of a physical or neurological condition that interferes with study procedures
  • Social and/or personal circumstances that interfere with the ability to return for assessments
  • Patients taking benzodiazepines or Z-drugs that have a significant effect on sleep EEG
  • Recent DBS implant (≤ 6 months)
  • Inability to perform outcome assessments without walking aid
  • Skin disorders/problems/allergies in face/ear area that could worsen with electrode application (e.g. nickel allergy)

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

40 participants in 2 patient groups

Sham arm
Sham Comparator group
Description:
Control targeted auditory stimulation during sleep during motor rehabilitation (TASS sham intervention)
Treatment:
Other: TASS Intervention (Sham)
Verum arm
Experimental group
Description:
Targeted auditory stimulation during sleep during motor rehabilitation (TASS verum intervention)
Treatment:
Other: TASS Intervention (Verum)

Trial contacts and locations

1

Loading...

Central trial contact

Christian Baumann, Prof. Dr. med.; Angelina Maric, Dr. phil.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems